Search Browse Earnings

Rallybio Corp — SlamSEC

Rallybio Corp

Nasdaq:RLYB

Pharmaceutical Preparations·NEW HAVEN, CT

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$600,000

FY 2024

Adj. EBITDA

-$78.8M

-13130.3% margin

FY 2024

Net Income

-$74.6M

-12427.3% margin

FY 2024

EPS (Diluted)

-$1.84

FY 2024

Stock Price

$10.82

+0.0%

2026-03-09

52W Range

$1.76 – $11.49

P/E Ratio

-5.9x

Market Cap

$457.1M

Cash

$24.5M

FY 2024

Total Debt

—

Net Cash

$24.5M

FY 2024

Enterprise Value

$432.6M

Debt / EBITDA

0.3x

FY 2024

EV / EBITDA

-5.5x

Employees

—

CFO

Lieber Jonathan I